FibroGen has announced topline data from the Phase 3 LELANTOS-1 study of pamrevlumab, their investigational monoclonal antibody, for non-ambulatory patients with Duchenne muscular dystrophy.

Though the drug was generally safe and well tolerated, the trial did not meet the primary endpoint of Performance of the Upper Limb 2.0 (PUL 2.0) score at week 52 compared to baseline.

“While disappointed with these results, we look forward to sharing the data at a future medical conference to contribute towards the understanding of this devastating disease.”

Enrique Contern, FibroGen CEO

The secondary pamrevlumab study, LELANTOS-2, for patients with Duchenne is still active (including a site in London, Ontario at Children’s Hospital – London Health Sciences Centre) and is due to report results in the third quarter of 2023.